{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:57:08Z","timestamp":1780721828017,"version":"3.54.1"},"reference-count":48,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2018.0287","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:20:38Z","timestamp":1525252838000},"source":"Crossref","is-referenced-by-count":13,"title":["Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation"],"prefix":"10.3238","author":[{"given":"Gunnar H.","family":"Heine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Brandenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan H.","family":"Schirmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2018,4,27]]},"reference":[{"key":"10.3238\/arztebl.2018.0287_ref1","doi-asserted-by":"crossref","unstructured":"Girndt M, Trocchi P, Scheidt-Nave C, Markau S, Stang A: The prevalence of renal failure\u2014results from the German Health Interview and Examination Survey for Adults, 2008\u20132011 (DEGS1). Dtsch Arztebl Int 2016; 113: 85\u201391","DOI":"10.3238\/arztebl.2016.0085"},{"key":"10.3238\/arztebl.2018.0287_ref2","doi-asserted-by":"crossref","unstructured":"Eckardt KU, Coresh J, Devuyst O, et al.: Evolving importance of kidney disease: from subspecialty to global health burden. Lancet\u00a02013; 382: 158\u201369","DOI":"10.1016\/S0140-6736(13)60439-0"},{"key":"10.3238\/arztebl.2018.0287_ref3","doi-asserted-by":"crossref","unstructured":"Palmer SC, Sciancalepore M, Strippoli GF: Trial quality in nephrology: how are we measuring up? Am J Kidney Dis 2011; 58: 335\u20137","DOI":"10.1053\/j.ajkd.2011.06.006"},{"key":"10.3238\/arztebl.2018.0287_ref4","doi-asserted-by":"crossref","unstructured":"Bjorck S, Palaszewski B, Friberg L, Bergfeldt L: Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke 2013; 44: 3103\u20138","DOI":"10.1161\/STROKEAHA.113.002329"},{"key":"10.3238\/arztebl.2018.0287_ref5","doi-asserted-by":"crossref","unstructured":"Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M: Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc 2015\u201a 4: e001486","DOI":"10.1161\/JAHA.114.001486"},{"key":"10.3238\/arztebl.2018.0287_ref6","doi-asserted-by":"crossref","unstructured":"Liao JN, Chao TF, Liu CJ, et al.: Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. Kidney Int 2015; 87: 1209\u201315","DOI":"10.1038\/ki.2014.393"},{"key":"10.3238\/arztebl.2018.0287_ref7","doi-asserted-by":"crossref","unstructured":"Konigsbrugge O, Posch F, Antlanger M, et al.: Prevalence of atrial fibrillation and antithrombotic therapy in hemodialysis patients: cross-sectional results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI). PloS One 2017; 12: e0169400","DOI":"10.1371\/journal.pone.0169400"},{"key":"10.3238\/arztebl.2018.0287_ref8","doi-asserted-by":"crossref","unstructured":"Bansal N, Xie D, Tao K, et al.: Atrial fibrillation and risk of ESRD in adults with CKD. Clin J Am Soc Nephrol 2016; 11: 1189\u201396","DOI":"10.2215\/CJN.10921015"},{"key":"10.3238\/arztebl.2018.0287_ref9","doi-asserted-by":"crossref","unstructured":"Miyasaka Y, Barnes ME, Gersh BJ, et al.: Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119\u201325","DOI":"10.1161\/CIRCULATIONAHA.105.595140"},{"key":"10.3238\/arztebl.2018.0287_ref10","doi-asserted-by":"crossref","unstructured":"Dulli DA, Stanko H, Levine RL: Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology 2003; 22: 118\u201323","DOI":"10.1159\/000068743"},{"key":"10.3238\/arztebl.2018.0287_ref11","doi-asserted-by":"crossref","unstructured":"Marini C, De Santis F, Sacco S, et al.: Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005; 36: 1115\u20139","DOI":"10.1161\/01.STR.0000166053.83476.4a"},{"key":"10.3238\/arztebl.2018.0287_ref12","doi-asserted-by":"crossref","unstructured":"Connolly S, Pogue J, Hart R, et al.: Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903\u201312","DOI":"10.1016\/S0140-6736(06)68845-4"},{"key":"10.3238\/arztebl.2018.0287_ref13","doi-asserted-by":"crossref","unstructured":"Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492\u2013501","DOI":"10.7326\/0003-4819-131-7-199910050-00003"},{"key":"10.3238\/arztebl.2018.0287_ref14","doi-asserted-by":"crossref","unstructured":"Friberg L, Rosenqvist M, Lip GYH: Net clinical benefit of warfarin in patients with atrial fibrillation\/CLINICAL PERSPECTIVE. Circulation 2012; 125: 2298\u2013307","DOI":"10.1161\/CIRCULATIONAHA.111.055079"},{"key":"10.3238\/arztebl.2018.0287_ref15","doi-asserted-by":"crossref","unstructured":"Banerjee A, Fauchier L, Vourc\u2019h P, et al. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley atrial fibrillation project. J Am Coll Cardiol 2013; 61:2079\u201387","DOI":"10.1016\/j.jacc.2013.02.035"},{"key":"10.3238\/arztebl.2018.0287_ref16","doi-asserted-by":"crossref","unstructured":"Jun M, James MT, Manns BJ, et al.: The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ 2015; 350: h246","DOI":"10.1136\/bmj.h246"},{"key":"10.3238\/arztebl.2018.0287_ref17","doi-asserted-by":"crossref","unstructured":"Brandenburg VM, Schurgers LJ, Kaesler N, et al.: Prevention of vasculopathy by vitamin K supplementation: can we turn fiction into fact? Atherosclerosis 2015; 240: 10\u20136","DOI":"10.1016\/j.atherosclerosis.2015.02.040"},{"key":"10.3238\/arztebl.2018.0287_ref18","doi-asserted-by":"crossref","unstructured":"Schurgers LJ, Joosen IA, Laufer EM, et al.: Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype. PLoS One 2012; 7: e43229","DOI":"10.1371\/journal.pone.0043229"},{"key":"10.3238\/arztebl.2018.0287_ref19","doi-asserted-by":"crossref","unstructured":"Schurgers LJ, Teunissen KJ, Knapen MH, et al.: Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol 2005; 25: 1629\u201333","DOI":"10.1161\/01.ATV.0000173313.46222.43"},{"key":"10.3238\/arztebl.2018.0287_ref20","doi-asserted-by":"crossref","unstructured":"Brandenburg VM, Kramann R, Rothe H, et al.: Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol Dial Transplant 2017; 32: 126\u201332","DOI":"10.1093\/ndt\/gfv438"},{"key":"10.3238\/arztebl.2018.0287_ref21","doi-asserted-by":"crossref","unstructured":"B\u00f6hm M, Ezekowitz MD, Connolly SJ, et al.: Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY Trial. J Am Coll Cardiol 2015; 65: 2481\u201393","DOI":"10.1016\/j.jacc.2015.03.577"},{"key":"10.3238\/arztebl.2018.0287_ref22","doi-asserted-by":"crossref","unstructured":"Herzog CA, Asinger RW, Berger AK, et al.: Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011\u201a 80: 572\u201386","DOI":"10.1038\/ki.2011.223"},{"key":"10.3238\/arztebl.2018.0287_ref23","unstructured":"January CT, Wann LS, Alpert JS, et al.: 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: e1\u201376"},{"key":"10.3238\/arztebl.2018.0287_ref24","doi-asserted-by":"crossref","unstructured":"Kirchhof P, Benussi S, Kotecha D, et al.: 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893\u2013962","DOI":"10.5603\/KP.2016.0172"},{"key":"10.3238\/arztebl.2018.0287_ref25","doi-asserted-by":"crossref","unstructured":"Hart RG, Eikelboom JW, Ingram AJ, Herzog CA: Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol 2012; 8: 569\u201378","DOI":"10.1038\/nrneph.2012.160"},{"key":"10.3238\/arztebl.2018.0287_ref26","doi-asserted-by":"crossref","unstructured":"Hart RG, Pearce LA, Asinger RW, Herzog CA: Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 2599\u2013604","DOI":"10.2215\/CJN.02400311"},{"key":"10.3238\/arztebl.2018.0287_ref27","doi-asserted-by":"crossref","unstructured":"Wizemann V, Tong L, Satayathum S, et al.: Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010; 77: 1098\u2013106","DOI":"10.1038\/ki.2009.477"},{"key":"10.3238\/arztebl.2018.0287_ref28","doi-asserted-by":"crossref","unstructured":"Chan KE, Lazarus JM, Thadhani R, Hakim RM: Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009; 20: 2223\u201333","DOI":"10.1681\/ASN.2009030319"},{"key":"10.3238\/arztebl.2018.0287_ref29","doi-asserted-by":"crossref","unstructured":"Tan J, Liu S, Segal JB, Alexander GC, McAdams-DeMarco M: Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis. BMC Nephrol 2016; 17: 157","DOI":"10.1186\/s12882-016-0368-6"},{"key":"10.3238\/arztebl.2018.0287_ref30","doi-asserted-by":"crossref","unstructured":"Jun M, James MT, Ma Z, et al.: Warfarin initiation, atrial fibrillation, and kidney function: comparative effectiveness and safety of warfarin in older adults with newly diagnosed atrial fibrillation. Am J Kidney Dis 2017; 69: 734\u201343","DOI":"10.1053\/j.ajkd.2016.10.018"},{"key":"10.3238\/arztebl.2018.0287_ref31","doi-asserted-by":"crossref","unstructured":"Ruff CT, Giugliano RP, Braunwald E, et al.: Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955\u201362","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"10.3238\/arztebl.2018.0287_ref32","doi-asserted-by":"crossref","unstructured":"Graham DJ, Reichman ME, Wernecke M, et al.: Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 2016; 176: 1662\u201371","DOI":"10.1001\/jamainternmed.2016.5954"},{"key":"10.3238\/arztebl.2018.0287_ref33","doi-asserted-by":"crossref","unstructured":"Graham DJ, Reichman ME, Wernecke M, et al.: Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131: 157\u201364","DOI":"10.1161\/CIRCULATIONAHA.114.012061"},{"key":"10.3238\/arztebl.2018.0287_ref34","doi-asserted-by":"crossref","unstructured":"Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G: Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc 2015; 4 (4). pii: e001798","DOI":"10.1161\/JAHA.115.001798"},{"key":"10.3238\/arztebl.2018.0287_ref35","doi-asserted-by":"crossref","unstructured":"Yao X, Abraham NS, Sangaralingham LR, et al.: Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc 2016; 5 (6). pii: e003725","DOI":"10.1161\/JAHA.116.003725"},{"key":"10.3238\/arztebl.2018.0287_ref36","doi-asserted-by":"crossref","unstructured":"Hohnloser SH, Basic E, Nabauer M: Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study. Clin Res Cardiol 2017; 106: 618\u201328","DOI":"10.1007\/s00392-017-1098-x"},{"key":"10.3238\/arztebl.2018.0287_ref37","doi-asserted-by":"crossref","unstructured":"Chan KE, Giugliano RP, Patel MR, et al.: Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J Am Coll Cardiol 2016; 67: 2888\u201399","DOI":"10.1016\/j.jacc.2016.02.082"},{"key":"10.3238\/arztebl.2018.0287_ref38","doi-asserted-by":"crossref","unstructured":"Schlieper G, Schwenger V, Remppis A, et al.: [Anticoagulation in patients with chronic kidney disease: recommendations from the working group \u201eHeart-Kidney\u201c of the German Cardiac Society and the German Society of Nephrology]. Internist (Berl) 2017; 58: 512\u201321","DOI":"10.1007\/s00108-017-0220-5"},{"key":"10.3238\/arztebl.2018.0287_ref39","doi-asserted-by":"crossref","unstructured":"Coresh J, Turin TC, Matsushita K, et al.: Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 2014; 311: 2518\u201331","DOI":"10.1001\/jama.2014.6634"},{"key":"10.3238\/arztebl.2018.0287_ref40","doi-asserted-by":"crossref","unstructured":"Naimark DM, Grams ME, Matsushita K, et al.: Past decline versus current eGFR and subsequent mortality risk. J Am Soc Nephrol 2016; 27: 2456\u201366","DOI":"10.1681\/ASN.2015060688"},{"key":"10.3238\/arztebl.2018.0287_ref41","doi-asserted-by":"crossref","unstructured":"Soliman EZ, Prineas RJ, Go AS, et al.: Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010; 159: 1102\u20137","DOI":"10.1016\/j.ahj.2010.03.027"},{"key":"10.3238\/arztebl.2018.0287_ref42","doi-asserted-by":"crossref","unstructured":"Schwartz JB: Potential effect of substituting estimated glomerular filtration rate for estimated creatinine clearance for dosing of direct oral anticoagulants. J Am Geriatr Soc 2016; 64: 1996\u20132002","DOI":"10.1111\/jgs.14288"},{"key":"10.3238\/arztebl.2018.0287_ref43","doi-asserted-by":"crossref","unstructured":"Steinberg BA, Shrader P, Thomas L, et al.: Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry. J Am Coll Cardiol 2016; 68: 2597\u2013604","DOI":"10.1016\/j.jacc.2016.09.966"},{"key":"10.3238\/arztebl.2018.0287_ref44","doi-asserted-by":"crossref","unstructured":"De Vriese AS, Caluwe R, Bailleul E, et al.: Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis 2015; 66: 91\u20138","DOI":"10.1053\/j.ajkd.2015.01.022"},{"key":"10.3238\/arztebl.2018.0287_ref45","doi-asserted-by":"crossref","unstructured":"Mavrakanas TA, Samer CF, Nessim SJ, Frisch G, Lipman ML: Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol 2017; 28: 2241\u20138","DOI":"10.1681\/ASN.2016090980"},{"key":"10.3238\/arztebl.2018.0287_ref46","doi-asserted-by":"crossref","unstructured":"Wang X, Tirucherai G, Marbury TC, et al.: Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol 2016; 56: 628\u201336","DOI":"10.1002\/jcph.628"},{"key":"10.3238\/arztebl.2018.0287_ref47","doi-asserted-by":"crossref","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ: Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137: 263\u201372","DOI":"10.1378\/chest.09-1584"},{"key":"10.3238\/arztebl.2018.0287_ref48","doi-asserted-by":"crossref","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY: A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093\u2013100","DOI":"10.1378\/chest.10-0134"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2018.0287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T13:36:13Z","timestamp":1638797773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2018.0287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,27]]},"references-count":48,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2018.0287","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,27]]}}}